| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by LCR.
Page 2: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 301 | 14 | 24 | 658 1977 TERATOLOGY 16(1):79-82 MCBRIDE WG THALIDOMIDE EMBRYOPATHY | 11 | 29 |
| 302 | 14 | 36 | 826 1983 MEDICAL HYPOTHESES 10(4):437-443 HENDLER SS; MCCARTY MF THALIDOMIDE FOR AUTOIMMUNE-DISEASE | 13 | 14 |
| 303 | 14 | 33 | 1002 1990 ACTA ENDOCRINOLOGICA 123(1):79-83 LUEPRASITSAKUL W; ABEND S; ALEX S; REINHARDT W; APPEL MC; BRAVERMAN LE EFFECT OF THALIDOMIDE ON THE INCIDENCE OF IODINE-INDUCED AND SPONTANEOUS LYMPHOCYTIC THYROIDITIS AND SPONTANEOUS DIABETES-MELLITUS IN THE BB/WOR RAT | 2 | 2 |
| 304 | 14 | 20 | 1037 1991 BRITISH JOURNAL OF HAEMATOLOGY 78(1):23-27 HENEY D; NORFOLK DR; WHEELDON J; BAILEY CC; LEWIS IJ; BARNARD DL THALIDOMIDE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 59 | 72 |
| 305 | 14 | 29 | 1160 1994 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 91(9):4082-4085 DAMATO RJ; LOUGHNAN MS; FLYNN E; FOLKMAN J THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS | 326 | 719 |
| 306 | 14 | 24 | 1211 1995 LIFE SCIENCES 58(4):337-348 Nogueira AC; Neubert R; Felies A; JacobMuller U; Frankus E; Neubert D Thalidomide derivatives and the immune system .6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets | 2 | 3 |
| 307 | 14 | 21 | 1312 1997 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 41(12):2797-2799 Piscitelli SC; Figg WD; Hahn B; Kelly G; Thomas S; Walker RE Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients | 22 | 25 |
| 308 | 14 | 27 | 1314 1997 BIOCHEMICAL PHARMACOLOGY 53(10):1553-1557 Nicolai S; Sies H; Stahl W Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human skin fibroblasts | 6 | 11 |
| 309 | 14 | 21 | 1322 1997 CHEMTECH 27(1):21-25 Muller GW Thalidomide: From tragedy to new drug discovery | 4 | 9 |
| 310 | 14 | 23 | 1417 1998 BONE MARROW TRANSPLANTATION 21(6):577-581 Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasiulli A; Vassallo E; Miniero R; Uderzo C The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children | 26 | 36 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 311 | 14 | 30 | 1445 1998 JOURNAL OF IMMUNOLOGY 161(8):4236-4243 Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production | 33 | 49 |
| 312 | 14 | 27 | 1557 1999 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 5(5):261-267 Scoville CD; Reading JC Open trial of thalidomide in the treatment of rheumatoid arthritis | 1 | 1 |
| 313 | 14 | 40 | 1598 1999 REPRODUCTIVE TOXICOLOGY 13(6):547-554 Hansen JM; Carney EW; Harris C Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro | 6 | 10 |
| 314 | 14 | 17 | 1599 1999 REVUE DE MEDECINE INTERNE 20(7):567-570 de Wazieres B; Gil H; Magy N; Berthier S; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low dose of thalidomide. Pilot study in 17 patients | 3 | 8 |
| 315 | 14 | 41 | 1738 2000 JOURNAL OF CHROMATOGRAPHY A 876(1-2):157-167 Meyring M; Chankvetadze B; Blaschke G Simultaneous separation and enantioseparation of thalidomide and its hydroxylated metabolites using high-performance liquid chromatography in common-size columns, capillary liquid chromatography and nonaqueous capillary electrochromatography | 3 | 31 |
| 316 | 14 | 57 | 1774 2000 ONCOLOGY-NEW YORK 14(12):11-16 Rajkumar SV Thalidomide in multiple myeloma | 9 | 17 |
| 317 | 14 | 32 | 1826 2001 BIOORGANIC & MEDICINAL CHEMISTRY 9(4):1059-1065 Gutschow M; Hecker T; Thiele A; Hauschildt S; Eger K Aza analogues of thalidomide: Synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro | 3 | 8 |
| 318 | 14 | 41 | 2002 2001 RHEUMATOLOGY 40(8):933-938 Kari JA; Shah V; Dillon MJ Behcet's disease in UK children: clinical features and treatment including thalidomide | 5 | 14 |
| 319 | 14 | 18 | 2160 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(6):S158-S161 Huang F; Wei JCC; Breban M Thalidomide in ankylosing spondylitis | 0 | 1 |
| 320 | 14 | 22 | 2198 2002 HAEMATOLOGICA 87(4):345-346 [Anon] Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 321 | 14 | 28 | 2212 2002 JAPANESE JOURNAL OF CANCER RESEARCH 93(9):1029-1036 Kakimoto T; Hattori Y; Okamoto S; Sato N; Kamata T; Yamaguchi M; Morita K; Yamada T; Takayama N; Uchida H; Shimada N; Tanigawara Y; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome | 3 | 3 |
| 322 | 14 | 25 | 2228 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(2):135-139 Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease | 8 | 13 |
| 323 | 14 | 18 | 2281 2002 PHARMACEUTICAL RESEARCH 19(8):1232-1235 Goosen C; Laing TJ; du Plessis J; Goosen TC; Rao TB; Flynn GL Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs | 3 | 3 |
| 324 | 14 | 24 | 2321 2003 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 47(8):2445-2449 Giamarellos-Bourboulis EJ; Poulaki H; Kostomitsopoulos N; Dontas I; Perrea D; Karayannacos PE; Giamarellou H Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide | 0 | 1 |
| 325 | 14 | 33 | 2453 2003 EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 15(9):951-957 Muriel P; Fernandez-Martinez E; Perez-Alvarez V; Lara-Ochoa F; Ponce S; Garcia J; Shibayama M; Tsutsumi V Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat | 0 | 1 |
| 326 | 14 | 23 | 2556 2003 SEMINARS IN HEMATOLOGY 40(4):8-16 Dimopoulos MA; Anagnostopoulos A Thalidomide in relapsed/refractory multiple myeloma: Pivotal trials conducted outside the United States | 0 | 0 |
| 327 | 14 | 35 | 2586 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(2):421-425 Perino S; Contino-Pepin C; Satchi-Fainaro R; Butterfield C; Pucci B Inhibition of angiogenesis by THAM-derived cotelomers endowed with thalidomide moieties | 0 | 0 |
| 328 | 14 | 20 | 2660 2004 LEUKEMIA & LYMPHOMA 45(4):735-738 Balleari E; Ghio R; Falcone A; Musto P Possible multiple myeloma dedifferentiation following thalidomide therapy: A report of four cases | 0 | 0 |
| 329 | 14 | 27 | 2680 2004 ONCOLOGY REPORTS 11(1):93-95 Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma | 0 | 0 |
| 330 | 14 | 24 | 2681 2004 ONKOLOGIE 27(2):150-154 Steurer M; Spizzo G; Mitterer M; Gastl G Low-dose thalidomide for multiple myeloma: Interim analysis of a compassionate use program | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 331 | 14 | 32 | 2685 2004 UROLOGY 63(6):1061-1065 Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma | 0 | 0 |
| 332 | 13 | 23 | 106 1962 JOURNAL OF PEDIATRICS 61(1):153-& BLATTNER RJ DRUGS IN PREGNANCY - THALIDOMIDE | 3 | 3 |
| 333 | 13 | 27 | 351 1965 POULTRY SCIENCE 44(6):1583-& NABER EC; LARGENT EJ THALIDOMIDE TERATOGENESIS IN DEVELOPING CHICK EMBRYO AND ITS RELATIONSHIP TO VITAMIN METABOLISM | 1 | 2 |
| 334 | 13 | 41 | 356 1965 TOXICOLOGY AND APPLIED PHARMACOLOGY 7(2):268-& FRATTA ID; SIGG EB; MAIORANA K TERATOGENIC EFFECTS OF THALIDOMIDE IN RABBITS RATS HAMSTERS AND MICE | 15 | 34 |
| 335 | 13 | 20 | 369 1966 CANADIAN MEDICAL ASSOCIATION JOURNAL 95(9):390-& MONGEAU M; GINGRAS G; SHERMAN ED; HEBERT B; HUTCHISO.J; CORRIVEA.C MEDICAL AND PSYCHOSOCIAL ASPECTS OF HABILITATION OF THALIDOMIDE CHILDREN | 0 | 2 |
| 336 | 13 | 41 | 431 1967 DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY 9(1):87-& METCALF WK RELATION OF VITAMIN-B COMPLEX TO EFFECT OF THALIDOMIDE ON SENSITIVITY OF INTRACELLULAR HAEMOGLOBIN TO OXIDATION | 0 | 1 |
| 337 | 13 | 34 | 527 1971 MONATSHEFTE FUR CHEMIE 102(2):609-& KOCH H; KOTLAN J; FARKOUH E; LINDNER M THALIDOMIDE ANALOGUES .3. | 8 | 14 |
| 338 | 13 | 145 | 662 1977 ZEITSCHRIFT FUR NATURFORSCHUNG C-A JOURNAL OF BIOSCIENCES 32(3-4):241-248 HANAUSKEABEL H; GUNZLER V INHIBITION OF HUMAN PROLYL HYDROXYLASE AS COMMON BIOCHEMICAL DENOMINATOR OF NON-SEDATIVE EFFECTS OF THALIDOMIDE IN MAN | 6 | 8 |
| 339 | 13 | 39 | 745 1981 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 31-1(6):941-949 HELM FC; FRANKUS E; FRIDERICHS E; GRAUDUMS I; FLOHE L COMPARATIVE TERATOLOGICAL INVESTIGATION OF COMPOUNDS STRUCTURALLY AND PHARMACOLOGICALLY RELATED TO THALIDOMIDE | 0 | 54 |
| 340 | 13 | 34 | 818 1983 DEVELOPMENT GROWTH & DIFFERENTIATION 25(4):361-373 MCBRIDE WG; VARDY PH PATHOGENESIS OF THALIDOMIDE TERATOGENESIS IN THE MARMOSET (CALLITHRIX-JACCHUS) - EVIDENCE SUGGESTING A POSSIBLE TROPHIC INFLUENCE OF CHOLINERGIC NERVES IN LIMB MORPHOGENESIS | 1 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 341 | 13 | 38 | 909 1985 TERATOLOGY 32(1):133-144 NEWMAN CGH TERATOGEN UPDATE - CLINICAL ASPECTS OF THALIDOMIDE EMBRYOPATHY - A CONTINUING PREOCCUPATION | 8 | 27 |
| 342 | 13 | 27 | 915 1986 BRITISH JOURNAL OF DERMATOLOGY 115(3):367-370 RAMSELAAR CG; BOONE RM; KLUINNELEMANS HC THALIDOMIDE IN THE TREATMENT OF NEURO-BEHCETS SYNDROME | 10 | 20 |
| 343 | 13 | 40 | 1018 1990 JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 49(6):564-581 DEIONGH RU A QUANTITATIVE ULTRASTRUCTURAL-STUDY OF MOTOR AND SENSORY LUMBOSACRAL NERVE ROOTS IN THE THALIDOMIDE-TREATED RABBIT FETUS | 3 | 3 |
| 344 | 13 | 17 | 1051 1991 TRANSPLANTATION 52(5):908-910 KEENAN RJ; EIRAS G; BURCKART GJ; STUART RS; HARDESTY RL; VOGELSANG G; GRIFFITH BP; ZEEVI A IMMUNOSUPPRESSIVE PROPERTIES OF THALIDOMIDE - INHIBITION OF INVITRO LYMPHOCYTE-PROLIFERATION ALONE AND IN COMBINATION WITH CYCLOSPORINE OR FK506 | 39 | 44 |
| 345 | 13 | 24 | 1141 1994 FOLIA BIOLOGICA 40(4):161-171 BILA V; KREN V EVIDENCE FOR TERATOGENICITY OF THALIDOMIDE USING CONGENIC AND RECOMBINANT INBRED RAT STRAINS | 0 | 10 |
| 346 | 13 | 28 | 1252 1996 CHIRALITY 8(1):11-17 Reepmeyer JC Separation of R-and S-thalidomide by reversed-phase HPLC with beta-cyclodextrin in the mobile phase | 6 | 18 |
| 347 | 13 | 32 | 1293 1996 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 93(15):7552-7556 Turk BE; Jiang H; Liu JO Binding of thalidomide to alpha(1)-acid glyeoprotein may be involved in its inhibition of tumor necrosis factor alpha production | 39 | 47 |
| 348 | 13 | 25 | 1328 1997 CLINICAL INFECTIOUS DISEASES 24(6):1223-1227 Haslett P; Tramontana J; Burroughs M; Hempstead M; Kaplan G Adverse reactions to thalidomide in patients infected with human immunodeficiency virus | 22 | 30 |
| 349 | 13 | 25 | 1396 1998 ANNALS OF INTERNAL MEDICINE 128(6):443-+ Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - A randomized, double-blind, placebo-controlled trial | 67 | 126 |
| 350 | 13 | 27 | 1406 1998 BIOCHEMICAL PHARMACOLOGY 55(11):1827-1834 Bauer KS; Dixon SC; Figg WD Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent | 80 | 120 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 351 | 13 | 23 | 1424 1998 CHIRALITY 10(3):223-228 Eriksson T; Bjorkman S; Roth B; Fyge A; Hoglund P Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis | 17 | 28 |
| 352 | 13 | 27 | 1437 1998 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 236(6):461-466 Kruse FE; Joussen AM; Rohrschneider K; Becker MD; Volcker HE Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor | 39 | 57 |
| 353 | 13 | 66 | 1463 1998 MEDICAL HYPOTHESES 50(4):313-318 Argiles JM; Carbo N; Lopez-Soriano FJ Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? | 11 | 12 |
| 354 | 13 | 16 | 1525 1999 CLEVELAND CLINIC JOURNAL OF MEDICINE 66(3):136-+ Calabrese LH Thalidomide's tightly controlled "comeback" | 3 | 3 |
| 355 | 13 | 34 | 1537 1999 ELECTROPHORESIS 20(12):2425-2431 Meyring M; Chankvetadze B; Blaschke G Enantioseparation of thalidomide and its hydroxylated metabolites using capillary electrophoresis with various cyclodextrins and their combinations as chiral buffer additives | 2 | 13 |
| 356 | 13 | 23 | 1569 1999 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 28(2):214-216 Weinstein TA; Sciubba JJ; Levine J Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease | 10 | 21 |
| 357 | 13 | 25 | 1585 1999 NATURE MEDICINE 5(5):582-585 Parman T; Wiley MJ; Wells PG Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity | 65 | 110 |
| 358 | 13 | 38 | 1681 2000 BRITISH JOURNAL OF CANCER 82(4):812-817 Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SRD; Ahern R; Smith IE; Gore ME Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer | 76 | 127 |
| 359 | 13 | 49 | 1694 2000 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 121(3):472-479 Guckian M; Dransfield I; Hay P; Dalgleish AG Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro | 4 | 6 |
| 360 | 13 | 49 | 1696 2000 CLINICAL IMMUNOLOGY 97(2):109-120 Oliver SJ; Moreira A; Kaplan G Immune stimulation in scleroderma patients treated with thalidomide | 11 | 15 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 361 | 13 | 20 | 1724 2000 IMMUNOPHARMACOLOGY 46(2):175-179 Shannon E; Aseffa A; Pankey G; Sandoval F; Lutz B Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+cells in their blood | 8 | 8 |
| 362 | 13 | 67 | 1740 2000 JOURNAL OF CLINICAL ONCOLOGY 18(13):2593-2602 Little RF; Wyvill KM; Pluda JM; Welles L; Marshall V; Figg WD; Newcomb FM; Tosato G; Feigal E; Steinberg SM; Whitby D; Goedert JJ; Yarchoan R Activity of thalidomide in AIDS-related Kaposis's sarcoma | 44 | 82 |
| 363 | 13 | 35 | 1907 2001 CLINICAL CANCER RESEARCH 7(9):2675-2681 Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma | 15 | 29 |
| 364 | 13 | 23 | 1949 2001 INTERNATIONAL IMMUNOPHARMACOLOGY 1(1):49-61 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B | 5 | 8 |
| 365 | 13 | 25 | 1952 2001 ISRAEL MEDICAL ASSOCIATION JOURNAL 3(9):644-648 Kenet G; Wardi J; Avni Y; Aeed H; Shirin H; Zaidel L; Hershkoviz R; Bruck R Amelioration of experimental colitis by thalidomide | 1 | 1 |
| 366 | 13 | 18 | 1961 2001 JOURNAL OF CLINICAL PHARMACOLOGY 41(10):1091-1097 Aweeka F; Trapnell C; Chernoff M; Jayewardene A; Spritzler J; Bellibas SE; Lizak P; Jacobson J Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251 | 6 | 7 |
| 367 | 13 | 21 | 1982 2001 NETHERLANDS JOURNAL OF MEDICINE 59(2):45-49 van de Poel MHW; Pasman PC; Schouten HC The use of thalidomide in chronic refractory graft versus host disease | 1 | 3 |
| 368 | 13 | 27 | 2022 2002 AMERICAN HEART JOURNAL 144(5):847-850 Gullestad L; Semb AG; Holt E; Skardal R; Ueland T; Yndestad A; Froland SS; Aukrust P Effect of thalidomide in patients with chronic heart failure | 1 | 4 |
| 369 | 13 | 33 | 2147 2002 CANCER 95(4):758-765 Daliani DD; Papandreou CN; Thall PF; Wang XM; Perez C; Oliva R; Pagliaro L; Amato R A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma | 5 | 10 |
| 370 | 13 | 14 | 2179 2002 EUROPEAN JOURNAL OF DERMATOLOGY 12(1):63-65 Frances C; El Khoury S; Gompel A; Becherel PA; Chosidow O; Piette JC Transient secondary amenorrhea in women treated by thalidomide | 1 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 371 | 13 | 38 | 2192 2002 GASTROENTEROLOGY 123(1):291-300 Enomoto N; Takei Y; Hirose M; Ikejima K; Miwa H; Kitamura T; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production | 3 | 12 |
| 372 | 13 | 36 | 2194 2002 GUT 50(2):196-200 Bauditz J; Wedel S; Lochs H Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease | 11 | 25 |
| 373 | 13 | 20 | 2197 2002 HAEMATOLOGICA 87(4):344-345 Ribatti D; Vacca A Is thalidomide a true anti-angiogenic molecule in multiple myeloma? | 1 | 1 |
| 374 | 13 | 15 | 2203 2002 HAUTARZT 53(11):744-748 Bohmeyer J; Achenbach A; Westenberger M; Stadler R Thalidomide therapy of cutaneous lupus erythematosus | 1 | 1 |
| 375 | 13 | 21 | 2227 2002 JOURNAL OF COMBINATORIAL CHEMISTRY 4(2):149-153 Xiao ZL; Schaefer K; Firestine S; Li PK Solid-phase synthesis of thalidomide and its analogues | 0 | 4 |
| 376 | 13 | 15 | 2232 2002 JOURNAL OF INFECTIOUS DISEASES 185(9):1359-1363 Wohl DA; Aweeka FT; Schmitz J; Pomerantz R; Cherng DW; Spritzler J; Fox L; Simpson D; Bell D; Holohan MK; Thomas S; Robinson W; Kaplan G; Teppler H; Natl Inst Allergy Infect Dis AIDS Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267 | 5 | 5 |
| 377 | 13 | 26 | 2336 2003 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 13(20):3415-3417 Man HW; Corral LG; Stirling DI; Muller GW alpha-fluoro-substituted thalidomide analogues | 1 | 1 |
| 378 | 13 | 35 | 2402 2003 BONE MARROW TRANSPLANTATION 32(2):165-170 Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease | 0 | 1 |
| 379 | 13 | 38 | 2444 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S59-S65 Amato RJ Thalidomide therapy for renal cell carcinoma | 0 | 1 |
| 380 | 13 | 23 | 2471 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 23(6):1651-1655 Kaicker S; McCrudden KW; Beck L; New T; Huang JZ; Frischer JS; Serur A; Kadenhe-Chiweshe A; Yokoi A; Kandel JJ; Yamashiro DJ Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 381 | 13 | 36 | 2482 2003 JOURNAL OF CLINICAL ONCOLOGY 21(20):3770-3776 Hernberg M; Virkkunen P; Bono P; Atinen H; Maenpaa H; Joensuu H Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma | 1 | 3 |
| 382 | 13 | 23 | 2497 2003 JOURNAL OF PHARMACY AND PHARMACOLOGY 55(12):1701-1706 Eriksson T; Hoglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis | 3 | 3 |
| 383 | 13 | 57 | 2523 2003 LEUKEMIA & LYMPHOMA 44(2):291-298 Ribas C; Colleoni GWB Advances in the treatment of multiple myeloma: The role of thalidomide | 0 | 1 |
| 384 | 13 | 28 | 2606 2004 CANCER CHEMOTHERAPY AND PHARMACOLOGY 53(5):377-383 Chung F; Wang LCS; Kestell P; Baguley BC; Ching LM Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor | 1 | 1 |
| 385 | 13 | 26 | 2634 2004 JOURNAL OF CHILD NEUROLOGY 19(4):250-257 Schoeman JF; Springer P; van Rensburg AJ; Swanevelder S; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study | 0 | 0 |
| 386 | 13 | 23 | 2650 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 51(1):126-131 Sansbury JC; Cocuroccia B; Jorizzo JL; Gubinelli E; Gisondi P; Girolomoni G Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients | 0 | 0 |
| 387 | 13 | 19 | 2683 2004 THROMBOSIS AND HAEMOSTASIS 91(4):834-836 Potenza L; Luppi M; Morselli M; Saviola A; Ferrari A; Riva G; Longo G; Marietta M; Torelli G Thrombotic complications associated with thalidomide in multiple myeloma: an old problem with new questions and quandaries in decision-making | 0 | 0 |
| 388 | 12 | 37 | 285 1964 JOURNAL OF PEDIATRICS 64(5):762-& BRENT RL DRUG TESTING IN ANIMALS FOR TERATOGENIC EFFECTS - THALIDOMIDE IN PREGNANT RAT | 5 | 39 |
| 389 | 12 | 26 | 337 1965 JOURNAL OF EMBRYOLOGY AND EXPERIMENTAL MORPHOLOGY 13:181-& DWORNIK JJ; MOORE KL SKELETAL MALFORMATIONS IN HOLTZMAN RAT EMBRYO FOLLOWING ADMINISTRATION OF THALIDOMIDE | 5 | 11 |
| 390 | 12 | 24 | 844 1984 ARTHRITIS AND RHEUMATISM 27(10):1118-1121 GUTIERREZRODRIGUEZ O THALIDOMIDE - A PROMISING NEW TREATMENT FOR RHEUMATOID-ARTHRITIS | 46 | 55 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 391 | 12 | 28 | 923 1986 JOURNAL OF NEUROLOGY 233(2):83-89 HESS CW; HUNZIKER T; KUPFER A; LUDIN HP THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - A PROSPECTIVE CLINICAL, NEUROPHYSIOLOGICAL AND PHARMACOGENETIC EVALUATION | 26 | 30 |
| 392 | 12 | 32 | 941 1987 ARCHIVES OF TOXICOLOGY 60(5):376-381 STERZ H; NOTHDURFT H; LEXA P; OCKENFELS H TERATOLOGIC STUDIES ON THE HIMALAYAN RABBIT - NEW ASPECTS OF THALIDOMIDE-INDUCED TERATOGENESIS | 6 | 10 |
| 393 | 12 | 22 | 1116 1994 ANNALS OF THE RHEUMATIC DISEASES 53(12):828-832 GARDNERMEDWIN JMM; SMITH NJ; POWELL RJ CLINICAL-EXPERIENCE WITH THALIDOMIDE IN THE MANAGEMENT OF SEVERE ORAL AND GENITAL ULCERATION IN CONDITIONS SUCH AS BEHCETS-DISEASE - USE OF NEUROPHYSIOLOGICAL STUDIES TO DETECT THALIDOMIDE NEUROPATHY | 53 | 72 |
| 394 | 12 | 24 | 1169 1995 ANNALS OF THORACIC SURGERY 59(2):277-282 UTHOFF K; ZEHR KJ; GAUDIN PB; KUMAR P; CHO PW; VOGELSANG G; HRUBAN RH; BAUMGARTNER WA; STUART RS THALIDOMIDE AS REPLACEMENT FOR STEROIDS IN IMMUNOSUPPRESSION AFTER LUNG TRANSPLANTATION | 16 | 18 |
| 395 | 12 | 43 | 1303 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(10):857-863 Moreira AL; Corral LG; Ye WG; Johnson B; Stirling D; Muller GW; Freedman VH; Kaplan G Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro | 36 | 47 |
| 396 | 12 | 22 | 1339 1997 IMMUNOPHARMACOLOGY 35(3):203-212 Shannon EJ; Morales MJ; Sandoval F Immunomodulatory assays to study structure-activity relationships of thalidomide | 10 | 13 |
| 397 | 12 | 21 | 1340 1997 IMMUNOPHARMACOLOGY 36(1):9-15 Shannon EJ; Sandoval F; Krahenbuhl JL Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha | 17 | 18 |
| 398 | 12 | 21 | 1345 1997 INTERNATIONAL JOURNAL OF ONCOLOGY 10(5):965-969 Nguyen M; Tran C; Barsky S; Sun JR; McBride W; Pegram M; Pietras R; Love S; Glaspy J Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies | 20 | 26 |
| 399 | 12 | 20 | 1383 1997 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 84(4):362-364 Elad S; Galili D; Garfunkel AA; Or R Thalidomide-induced perioral neuropathy | 2 | 3 |
| 400 | 12 | 15 | 1449 1998 JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES 21(14):2151-2163 Haque A; Stewart JT Determination of racemic thalidomide in human plasma by use of an avidin column and solid phase extraction | 3 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 401 | 12 | 14 | 1453 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 38(3):490-491 Hecker MS; Lebwohl MG Recalcitrant pyoderma gangrenosum: Treatment with thalidomide | 14 | 21 |
| 402 | 12 | 39 | 1482 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(13):1169-1179 Haslett PAJ; Klausner JD; Makonkawkeyoon S; Moreira A; Metatratip P; Boyle B; Kunachiwa W; Maneekarn N; Vongchan P; Corral LG; Elbeik T; Shen Z; Kaplan G Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients | 27 | 33 |
| 403 | 12 | 70 | 1536 1999 DRUGS 58(6):953-963 Ravot E; Lisziewicz J; Lori F New uses for old drugs in HIV infection - The role of hydroxyurea, cyclosporin and thalidomide | 3 | 15 |
| 404 | 12 | 52 | 1559 1999 JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME 81B(1):9-23 McCredie J; Willert HG Longitudinal limb deficiencies and the sclerotomes - An analysis of 378 dysmelic malformations induced by thalidomide | 0 | 7 |
| 405 | 12 | 15 | 1562 1999 JOURNAL OF CLINICAL PHARMACOLOGY 39(11):1162-1168 Teo SK; Colburn WA; Thomas SD Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers | 19 | 19 |
| 406 | 12 | 33 | 1697 2000 CLINICAL INFECTIOUS DISEASES 30(5):826-831 Aboulafia DM Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: Clinical improvement after initiation of thalidomide treatment | 1 | 4 |
| 407 | 12 | 44 | 1743 2000 JOURNAL OF INFECTIOUS DISEASES 181(3):954-965 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis | 18 | 27 |
| 408 | 12 | 41 | 1749 2000 JOURNAL OF MEDICAL PRIMATOLOGY 29(1):1-10 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M; Titti F Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys | 1 | 1 |
| 409 | 12 | 59 | 1831 2001 BLOOD 98(4):958-965 Raza A; Meyer P; Dutt D; Zorat F; Lisak L; Nascimben F; du Randt M; Kaspar C; Goldberg C; Loew J; Dar S; Gezer S; Venugopal P; Zeldis J Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes | 28 | 60 |
| 410 | 12 | 22 | 1888 2001 BRITISH JOURNAL OF HAEMATOLOGY 114(1):78-83 Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia | 12 | 23 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 411 | 12 | 56 | 1909 2001 CLINICAL CANCER RESEARCH 7(11):3349-3355 Fujita J; Mestre JR; Zeldis JB; Subbaramaiah K; Dannenberg AJ Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2 | 19 | 29 |
| 412 | 12 | 25 | 2009 2001 SEMINARS IN ONCOLOGY 28(6):593-596 Desikan RK; Jagannath S Therapeutic dilemmas with thalidomide in multiple myeloma: Case discussions | 2 | 2 |
| 413 | 12 | 27 | 2026 2002 AMERICAN JOURNAL OF MEDICINE 113(7):603-606 Bennett CL; Schumock GT; Desai AA; Kwaan HC; Raisch DW; Newlin R; Stadler W Thalidomide-associated deep vein thrombosis and pulmonary embolism | 3 | 6 |
| 414 | 12 | 26 | 2042 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):1-3 Mathe G Thalidomide, a drug which may protect the organism against some aggressive effects of the immunologic system | 0 | 0 |
| 415 | 12 | 35 | 2057 2002 BLOOD 99(12):4525-4530 Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Richardson PG; Hideshima T; Munshi NC; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications | 13 | 53 |
| 416 | 12 | 36 | 2136 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(2):288-296 Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia | 12 | 21 |
| 417 | 12 | 49 | 2165 2002 CLINICAL IMMUNOLOGY 102(3):225-236 Oliver SJ; Kikuchi T; Krueger JG; Kaplan G Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement | 4 | 7 |
| 418 | 12 | 19 | 2211 2002 INVESTIGATIONAL NEW DRUGS 20(4):389-393 Minor DR; Monroe D; Damico LA; Meng G; Suryadevara U; Elias L A phase II study of thalidomide in advanced metastatic renal cell carcinoma | 6 | 9 |
| 419 | 12 | 18 | 2229 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(3):233-235 Selby W Thalidomide in inflammatory bowel disease: Too little, too soon | 0 | 0 |
| 420 | 12 | 27 | 2319 2003 ANTICANCER RESEARCH 23(3B):2405-2411 Fujii T; Tachibana M; Dhar DK; Ueda S; Kinugasa S; Yoshimura H; Kohno H; Nagasue N Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 421 | 12 | 39 | 2467 2003 INTERNATIONAL JOURNAL OF DERMATOLOGY 42(5):372-375 Alfadley A; Al-Hawsawi K; Thestrup-Pedersen K; Al-Aboud K Treatment of prurigo nodularis with thalidomide: a case report and review of the literature | 0 | 0 |
| 422 | 12 | 32 | 2516 2003 LEUKEMIA 17(4):775-779 Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Thalidomide as initial therapy for early-stage myeloma | 11 | 18 |
| 423 | 12 | 13 | 2524 2003 LEUKEMIA & LYMPHOMA 44(6):989-991 Abdalla SH; Mahmoud S Thalidomide in relapsed or refractory multiple myeloma: How much and for how long? | 1 | 1 |
| 424 | 12 | 17 | 2527 2003 LEUKEMIA & LYMPHOMA 44(7):1147-1149 Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma | 1 | 1 |
| 425 | 12 | 18 | 2529 2003 LEUKEMIA & LYMPHOMA 44(11):1943-1946 Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H Low dose thalidomide in patients with relapsed or refractory multiple myeloma | 0 | 0 |
| 426 | 12 | 27 | 2530 2003 LEUKEMIA RESEARCH 27(10):909-914 Schey SA; Cavenagh J; Johnson R; Child JA; Oakervee H; Jones RW An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment | 0 | 1 |
| 427 | 12 | 35 | 2536 2003 MOLECULAR PHARMACOLOGY 64(2):415-420 Drucker L; Uziel O; Tohami T; Shapiro H; Radnay J; Yarkoni S; Lahav M; Lishner M Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma | 0 | 1 |
| 428 | 12 | 17 | 2555 2003 SEMINARS IN HEMATOLOGY 40(4):3-7 Alexanian R; Weber D; Anagnostopoulos A; Delasalle K; Wang M; Rankin K Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma | 0 | 0 |
| 429 | 12 | 23 | 2565 2003 XENOTRANSPLANTATION 10(5):470-474 Yamamoto S; Cooper DKC An investigation of the effect of thalidomide on anti-gal antibody production in baboons | 0 | 0 |
| 430 | 12 | 63 | 2566 2004 ACTA NEUROBIOLOGIAE EXPERIMENTALIS 64(1):1-9 Greig NH; Giordano T; Zhu XX; Yu QS; Perry TA; Holloway HW; Brossi A; Rogers JT; Sambamurti K; Lahiri DK Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 431 | 12 | 23 | 2578 2004 ANNALS OF PHARMACOTHERAPY 38(5):808-811 Sayarlioglu M; Kotan MC; Topcu N; Bayram I; Arslanturk H; Gul A Treatment of recurrent perforating intestinal ulcers with thalidomide in Behcet's disease | 0 | 0 |
| 432 | 12 | 43 | 2585 2004 BIOORGANIC & MEDICINAL CHEMISTRY 12(2):327-336 Capitosti SM; Hansen TP; Brown ML Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer | 0 | 0 |
| 433 | 12 | 17 | 2615 2004 DERMATOLOGY 208(2):149-152 Sander CS; Kaatz M; Elsner P Successful treatment of cutaneous Langerhans cell histiocytosis with thalidomide | 0 | 0 |
| 434 | 12 | 22 | 2666 2004 MAYO CLINIC PROCEEDINGS 79(7):875-882 Richardson P; Schlossman R; Jagannath S; Alsina M; Desikan R; Blood E; Weller E; Mitsiades C; Hideshima T; Davies F; Doss D; Freeman A; Bosch J; Patin J; Knight R; Zeldis J; Dalton W; Anderson K Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label Multicenter phase 2 study of efficacy, toxicity, and biological activity | 0 | 0 |
| 435 | 11 | 34 | 84 1962 BRITISH MEDICAL JOURNAL 2(5296):14-& LECK IM; MILLAR ELM INCIDENCE OF MALFORMATIONS SINCE INTRODUCTION OF THALIDOMIDE | 25 | 64 |
| 436 | 11 | 15 | 257 1963 PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE 113(3):619-& SHORB MS; POLLARD W; VASAITIS V; LUND PG; SMITH C EFFECT OF THALIDOMIDE TREATMENT OF HENS ON EMBRYONIC DEVELOPMENT AND FERTILITY | 3 | 7 |
| 437 | 11 | 24 | 279 1964 CANADIAN JOURNAL OF BIOCHEMISTRY AND PHYSIOLOGY 42(1):35-& BOYLEN JB; HORNE HH; JOHNSON WJ TERATOGENIC EFFECTS OF THALIDOMIDE + ITS METABOLITES ON DEVELOPING CHICK EMBRYO | 12 | 17 |
| 438 | 11 | 27 | 415 1967 AMERICAN JOURNAL OF VETERINARY RESEARCH 28(127):1823-& SZABO KT; STEELMAN RL EFFECTS OF MATERNAL THALIDOMIDE TREATMENT ON PREGNANCY FETAL DEVELOPMENT AND MORTALITY OF OFFSPRING IN RANDOM-BRED MICE | 12 | 12 |
| 439 | 11 | 34 | 464 1968 JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 31(6):543-& FULLERTON PM; OSULLIVA.DJ THALIDOMIDE NEUROPATHY - A CLINICAL ELECTROPHYSIOLOGICAL AND HISTOLOGICAL FOLLOW-UP STUDY | 86 | 129 |
| 440 | 11 | 17 | 536 1971 TOXICOLOGY AND APPLIED PHARMACOLOGY 18(1):208-& LEHMANN H; NIGGESCH.A TERATOLOGIC EFFECTS OF THALIDOMIDE IN HIMALAYAN RABBITS | 2 | 11 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 441 | 11 | 51 | 542 1972 ACTA PHARMACEUTICA SUECICA 9(6):543-562 JONSSON NA CHEMICAL STRUCTURE AND TERATOGENIC PROPERTIES .4. OUTLINE OF A CHEMICAL HYPOTHESIS FOR TERATOGENIC ACTION OF THALIDOMIDE | 15 | 27 |
| 442 | 11 | 28 | 620 1976 DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY 18(2):189-197 STEPHENSON JBP EPILEPSY - NEUROLOGICAL COMPLICATION OF THALIDOMIDE EMBRYOPATHY | 7 | 11 |
| 443 | 11 | 29 | 836 1983 TERATOLOGY 27(3):327-332 PARKHIE M; WEBB M EMBRYOTOXICITY AND TERATOGENICITY OF THALIDOMIDE IN RATS | 3 | 7 |
| 444 | 11 | 42 | 854 1984 JOURNAL OF ANATOMY 139(OCT):397-410 MCCREDIE J; NORTH K; DEIONGH R THALIDOMIDE DEFORMITIES AND THEIR NERVE SUPPLY | 3 | 6 |
| 445 | 11 | 35 | 918 1986 CLINICS IN PERINATOLOGY 13(3):555-573 NEWMAN CGH THE THALIDOMIDE SYNDROME - RISKS OF EXPOSURE AND SPECTRUM OF MALFORMATIONS | 6 | 19 |
| 446 | 11 | 19 | 963 1988 BONE MARROW TRANSPLANTATION 3(5):393-398 VOGELSANG GB; HESS AD; SANTOS GW THALIDOMIDE FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 31 | 38 |
| 447 | 11 | 33 | 995 1989 JOURNAL OF AUTOIMMUNITY 2(2):197-202 CRAIN E; MCINTOSH KR; GORDON G; PESTRONK A; DRACHMAN DB THE EFFECT OF THALIDOMIDE ON EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS | 7 | 9 |
| 448 | 11 | 14 | 1011 1990 EUROPEAN SURGICAL RESEARCH 22(6):336-339 EMRE S; SUMRANI N; HONG J BENEFICIAL EFFECT OF THALIDOMIDE AND CICLOSPORIN COMBINATION IN HETEROTOPIC CARDIAC TRANSPLANTATION IN RATS | 5 | 5 |
| 449 | 11 | 26 | 1035 1990 TRANSPLANTATION 49(1):20-25 TAMURA F; VOGELSANG GB; REITZ BA; BAUMGARTNER WA; HERSKOWITZ A COMBINATION THALIDOMIDE AND CYCLOSPORINE FOR CARDIAC ALLOGRAFT-REJECTION - COMPARISON WITH COMBINATION METHYLPREDNISOLONE AND CYCLOSPORINE | 20 | 26 |
| 450 | 11 | 27 | 1069 1992 LIFE SCIENCES 51(26):2107-2116 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .2. CHANGES IN RECEPTORS ON BLOOD-CELLS OF A HEALTHY VOLUNTEER | 32 | 38 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 451 | 11 | 33 | 1082 1993 ACTA OPHTHALMOLOGICA 71(2):238-245 STROMLAND K; MILLER MT THALIDOMIDE EMBRYOPATHY - REVISITED 27 YEARS LATER | 4 | 12 |
| 452 | 11 | 35 | 1106 1993 MOLECULAR AND CELLULAR BIOCHEMISTRY 129(2):195-200 WEGLICKI WB; STAFFORD RE; DICKENS BF; MAK IT; CASSIDY MM; PHILLIPS TM INHIBITION OF TUMOR-NECROSIS-FACTOR-ALPHA BY THALIDOMIDE IN MAGNESIUM-DEFICIENCY | 4 | 9 |
| 453 | 11 | 20 | 1147 1994 JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2 (9):2063-2067 REEPMEYER JC; RHODES MO; COX DC; SILVERTON JV CHARACTERIZATION AND CRYSTAL-STRUCTURE OF 2 POLYMORPHIC FORMS OF RACEMIC THALIDOMIDE | 3 | 4 |
| 454 | 11 | 26 | 1163 1994 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 40(5):543-548 VILANOVA M; RIBEIRO A; CARNEIRO J; ARALACHAVES M THE EFFECTS OF THALIDOMIDE TREATMENT ON AUTOIMMUNE-PRONE NZB AND MRL MICE ARE CONSISTENT WITH STIMULATION OF THE CENTRAL IMMUNE-SYSTEM .2. | 4 | 5 |
| 455 | 11 | 14 | 1168 1995 ANNALS OF CLINICAL BIOCHEMISTRY 32:79-83 BOUGHTON BJ; SHEEHAN TMT; WOOD J; OBRIEN D; BUTLER M; SIMPSON A; HALE KA HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY OF PLASMA THALIDOMIDE - STABILIZATION OF SPECIMENS AND DETERMINATION OF A TENTATIVE THERAPEUTIC RANGE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 17 | 17 |
| 456 | 11 | 31 | 1191 1995 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 49(1-2):1-6 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND GENETIC-DIFFERENCES IN DRUG-METABOLISM | 20 | 23 |
| 457 | 11 | 16 | 1231 1996 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 53(4):429-431 Minor JR; Piscitelli SC Thalidomide in diseases associated with human immunodeficiency virus infection | 3 | 4 |
| 458 | 11 | 43 | 1269 1996 INFLAMMATION 20(2):203-215 Kroger H; Miesel R; Dietrich A; Ohde M; Rajnavolgyi E; Ockenfels H Synergistic effects of thalidomide and poly(ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice | 1 | 12 |
| 459 | 11 | 14 | 1270 1996 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 111(1):13-17 SantosMendoza T; FavilaCastillo L; Oltra A; Tamariz J; Labarrios F; EstradaParra S; EstradaGarcia I Thalidomide and its metabolites have no effect on human lymphocyte proliferation | 7 | 9 |
| 460 | 11 | 39 | 1338 1997 GASTROENTEROLOGY 112(6):1823-1829 Sharpstone D; Rowbottom A; Francis N; Tovey G; Ellis D; Barrett M; Gazzard B Thalidomide: A novel therapy for microsporidiosis | 12 | 42 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 461 | 11 | 30 | 1357 1997 JOURNAL OF IMMUNOLOGY 159(10):5157-5161 Moller DR; Wysocka M; Greenlee BM; Ma XJ; Wahl L; Flockhart DA; Trinchieri G; Karp CL Inhibition of IL-12 production by thalidomide | 77 | 114 |
| 462 | 11 | 33 | 1452 1998 JOURNAL OF RHEUMATOLOGY 25(5):964-969 Oliver SJ; Cheng TP; Banquerigo ML; Brahn E The effect of thalidomide and 2 analogs on collagen induced arthritis | 15 | 31 |
| 463 | 11 | 18 | 1455 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(5):835-838 Lee JB; Koblenzer PS Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: A case report | 14 | 29 |
| 464 | 11 | 23 | 1488 1999 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 43(9):2305-2306 Ridoux O; Drancourt M Lack of in vitro antimicrosporidian activity of thalidomide | 1 | 1 |
| 465 | 11 | 51 | 1524 1999 CELLULAR AND MOLECULAR BIOLOGY 45(5):579-588 Gaffield W; Incardona JP; Kapur RP; Roelink H A looking glass perspective: Thalidomide and cyclopamine | 0 | 5 |
| 466 | 11 | 15 | 1571 1999 JOURNAL OF RHEUMATOLOGY 26(11):2344-2347 Keesal N; Wasserman MJ; Bookman A; Lapp V; Weber DA; Keystone EC Thalidomide in the treatment of refractory rheumatoid arthritis | 14 | 17 |
| 467 | 11 | 13 | 1594 1999 PEDIATRICS 103(4):art. no.-e44 Mehta P; Kedar A; Graham-Pole J; Skoda-Smith S; Wingard JR Thalidomide in children undergoing bone marrow transplantation: Series at a single institution and review of the literature | 0 | 10 |
| 468 | 11 | 22 | 1597 1999 PHARMACOTHERAPY 19(10):1177-1180 Horowitz SB; Stirling AL Thalidomide-induced toxic epidermal necrolysis | 10 | 10 |
| 469 | 11 | 30 | 1601 1999 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):312-316 Kalofoutis A; Monastirli A; Papapanagiotou A; Georgiou S; Pasmatzi E; Sakkis T; Bolsen K; Goerz G; Merk HF; Tsambaos D Alterations of rat liver phospholipid composition induced by oral thalidomide | 0 | 0 |
| 470 | 11 | 60 | 1614 2000 AMERICAN JOURNAL OF NEURORADIOLOGY 21(5):881-890 Cha S; Knopp EA; Johnson G; Litt A; Glass J; Gruber ML; Lu S; Zagzag D Dynamic contrast-enhanced T2*-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin | 2 | 23 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 471 | 11 | 41 | 1793 2000 TERATOLOGY 61(3):189-195 Stephens TD; Fillmore BJ Hypothesis: Thalidomide embryopathy - Proposed mechanism of action | 17 | 30 |
| 472 | 11 | 12 | 1807 2001 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 128(5):611-613 Estines O; Revuz J; Wolkenstein P; Bressieux JM; Roujeau JC; Cosnes A Sarcoidosis: thalidomide treatment in ten patients | 5 | 6 |
| 473 | 11 | 31 | 1898 2001 CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(6):541-544 Zhou SF; Kestell P; Tingle MD; Ching LM; Paxton JW A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide | 2 | 5 |
| 474 | 11 | 18 | 1969 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(2):178-181 Facchini S; Candusso M; Martelossi S; Liubich M; Panfili E; Ventura A Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: Preliminary results | 10 | 17 |
| 475 | 11 | 19 | 2052 2002 BJU INTERNATIONAL 89(6):591-595 Douglas ML; Reid JL; Hii SI; Jonsson JR; Nicol DL Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide | 1 | 4 |
| 476 | 11 | 23 | 2150 2002 CANCER CHEMOTHERAPY AND PHARMACOLOGY 50(3):186-192 Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide | 1 | 1 |
| 477 | 11 | 26 | 2171 2002 DERMATOLOGY 204(4):365-367 Nijsten T; Meuleman L; Schroyens W; Lambert J Thalidomide-induced morbilliform rash: Diagnosis and continuation of therapy, premedicated with methylprednisolone | 0 | 0 |
| 478 | 11 | 22 | 2204 2002 INTERNATIONAL IMMUNOPHARMACOLOGY 2(8):1143-1153 Shannon EJ; Sandoval FG Thalidomide can costimulate or suppress CD4(+) cells' ability to incorporate [H-3]-thymidine-dependence on the primary stimulant | 4 | 4 |
| 479 | 11 | 19 | 2218 2002 JOURNAL OF CLINICAL MICROBIOLOGY 40(6):2302-2304 Curley MJ; Hussein SA; Hassoun PM Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma | 0 | 0 |
| 480 | 11 | 38 | 2254 2002 LEUKEMIA 16(9):1609-1614 Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study | 7 | 12 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 481 | 11 | 20 | 2260 2002 LEUKEMIA & LYMPHOMA 43(12):2301-2307 Giovanni B; Michelle E; Letizia C; Filippo B; Paolo PP; Giuseppe V; Monia M; Gabriele P; Francesca Z; Ayalew T Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies | 0 | 0 |
| 482 | 11 | 47 | 2282 2002 PHARMACOTHERAPY 22(8):1019-1028 Cool RM; Herrington JD Thalidomide for the treatment of relapsed and refractory multiple myeloma | 1 | 1 |
| 483 | 11 | 15 | 2285 2002 REVUE DE MEDECINE INTERNE 23(7):651-656 Claudon A; Dietemann JL; De Compte AH; Hassler P Interest of thalidomide in cutaneo-mucous and hypothalamo-hypophyseal in Langerhans cell histiocytosis. | 1 | 1 |
| 484 | 11 | 28 | 2298 2003 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 17(5):677-682 Khan ZH; Simpson EJ; Cole AT; Holt M; MacDonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass | 0 | 1 |
| 485 | 11 | 30 | 2324 2003 ARCHIVES OF DERMATOLOGY 139(1):50-54 Housman TS; Jorizzo JL; McCarty MA; Grummer SE; Fleischer AB; Sutej PG Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus | 2 | 3 |
| 486 | 11 | 28 | 2404 2003 BONE MARROW TRANSPLANTATION 32(6):587-592 Ghobrial IM; Dispenzieri A; Bundy KL; Gastineau DA; Rajkumar SV; Therneau TM; Lacy MQ; Witzig TE; Litzow MR; Christensen BR; Hayman S; Pribula CG; Gertz MA Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma | 1 | 1 |
| 487 | 11 | 14 | 2411 2003 BRITISH JOURNAL OF DERMATOLOGY 149(2):432-433 Dobson CM; Parslew RA Exacerbation of psoriasis by thalidomide in Behcet's syndrome | 0 | 0 |
| 488 | 11 | 18 | 2446 2003 DERMATOLOGY 206(4):381-383 Kolivras A; De Maubeuge J; Andre J; Song M Thalidomide in refractory vulvar ulcerations associated with Crohn's disease | 1 | 1 |
| 489 | 11 | 25 | 2490 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(18):3793-3799 Luzzio FA; Mayorov AV; Ng SSW; Kruger EA; Figg WD Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNF alpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine | 0 | 0 |
| 490 | 11 | 52 | 2501 2003 JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION 10(3):252-259 Weeber M; Vos R; Klein H; de Jong-van den Berg LTW; Aronson AR; Molema G Generating hypotheses by discovering implicit associations in the literature: A case report of a search for new potential therapeutic uses for thalidomide. | 0 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 491 | 11 | 22 | 2544 2003 PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS 33:15-18 Rodeghiero F; Elice F Thalidomide and thrombosis | 0 | 1 |
| 492 | 11 | 14 | 2558 2003 SEMINARS IN HEMATOLOGY 40(4):33-38 Barlogie B Thalidomide and CC-5013 in multiple myeloma: The University of Arkansas experience | 0 | 0 |
| 493 | 11 | 28 | 2575 2004 ANNALS OF ONCOLOGY 15(1):134-138 Zervas K; Dimopoulos MA; Hatzicharissi E; Anagnostopoulos A; Papaioannou A; Mitsouli C; Panagiotidis P; Korantzis J; Tzilianos M; Maniatis A; Greek Myeloma Study Grp Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study | 0 | 0 |
| 494 | 11 | 36 | 2582 2004 ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 24(5):885-891 Park SJ; Kim HS; Yang HM; Park KW; Youn SW; Jeon SI; Kim DH; Koo BK; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
| 495 | 11 | 15 | 2601 2004 BRITISH JOURNAL OF HAEMATOLOGY 125(2):149-155 Waage A; Gimsing P; Juliusson G; Turesson I; Gulbrandsen N; Eriksson T; Hjorth M; Nielsen JL; Lenhoff S; Westin J; Wisloff F; Nordic Myeloma Study Grp Early response predicts thalidomide efficiency in patients with advanced multiple myeloma | 0 | 0 |
| 496 | 11 | 26 | 2621 2004 EUROPEAN JOURNAL OF HAEMATOLOGY 73(2):98-103 Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure | 0 | 0 |
| 497 | 11 | 40 | 2656 2004 LEUKEMIA 18(3):624-627 Kumar S; Witzig TE; Dispenzieri A; Lacy MQ; Wellik LE; Fonseca R; Lust JA; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma | 1 | 1 |
| 498 | 11 | 41 | 2682 2004 PATHOLOGY INTERNATIONAL 54(5):285-294 Du WL; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment | 0 | 0 |
| 499 | 10 | 23 | 100 1962 EUGENICS QUARTERLY 9(2):95-& JARVIK LF CONGENITAL MALFORMATIONS ATTRIBUTED TO SLEEPING PILL (THALIDOMIDE) | 0 | 1 |
| 500 | 10 | 16 | 210 1963 CANADIAN MEDICAL ASSOCIATION JOURNAL 89(19):987-& WEBB JF CANADIAN THALIDOMIDE EXPERIENCE | 0 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 501 | 10 | 44 | 308 1965 ACTA RADIOLOGICA-DIAGNOSIS 3(3):225-& ROSENDAL T APLASIA-HYPOPLASIA OF OTIC LABYRINTH AFTER THALIDOMIDE | 0 | 9 |
| 502 | 10 | 22 | 323 1965 CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 43(1):69-& MCCOLL JD; GLOBUS M; ROBINSON S AN ATTEMPTED REVERSAL OF THALIDOMIDE EMBRYOPATHY IN RAT BY GLUTAMINE | 7 | 10 |
| 503 | 10 | 19 | 398 1966 LANCET 1(7449):1240-& BORE PJ; SCOTHORN.RJ EFFECT OF THALIDOMIDE ON SURVIVAL OF SKIN HOMOGRAFTS IN RABBITS | 16 | 18 |
| 504 | 10 | 17 | 446 1968 AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 100(7):952-& GUSDON JP; COHEN C EFFECT OF THALIDOMIDE ON ANTIBODY RESPONSE | 21 | 22 |
| 505 | 10 | 27 | 485 1969 LABORATORY ANIMAL CARE 19(5P2):727-& FRATTA ID NICOTINAMIDE DEFICIENCY AND THALIDOMIDE - POTENTIAL TERATOGENIC DISTURBANCES IN LONG-EVANS RATS | 0 | 0 |
| 506 | 10 | 28 | 548 1972 ANNALEN DER CHEMIE-JUSTUS LIEBIG 755(NJAN):51-& KOCH H; KOTLAN J; FARKOUH E; PISCHEK G THALIDOMIDE ANALOGS .4. | 1 | 2 |
| 507 | 10 | 28 | 712 1979 TERATOLOGY 19(3):313-& THEISEN CT; BODIN JD; SVOBODA JA; PETTINELLI MW UNUSUAL MUSCLE ABNORMALITIES ASSOCIATED WITH THALIDOMIDE TREATMENT IN A RHESUS-MONKEY - CASE-REPORT | 0 | 2 |
| 508 | 10 | 24 | 762 1981 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES 78(4):2545-2548 GORDON GB; SPIELBERG SP; BLAKE DA; BALASUBRAMANIAN V THALIDOMIDE TERATOGENESIS - EVIDENCE FOR A TOXIC ARENE OXIDE METABOLITE | 48 | 89 |
| 509 | 10 | 18 | 892 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 12(1):85-90 GRINSPAN D SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 25 | 42 |
| 510 | 10 | 11 | 948 1987 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 64(3):289-292 EISENBUD L; HOROWITZ I; KAY B RECURRENT APHTHOUS STOMATITIS OF THE BEHCETS TYPE - SUCCESSFUL TREATMENT WITH THALIDOMIDE | 7 | 18 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 511 | 10 | 15 | 996 1989 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 488(2):417-425 WINCKLER K; KLINKMULLER KD; SCHMAHL HJ DETERMINATION OF THE THALIDOMIDE ANALOGS 2-(2,6-DIOXOPIPERIDINE-3-YL)PHTHALIMIDINE (EM 12), 2-(2,6-DIOXOPIPERIDINE-4-YL)PHTHALIMIDINE (EM 16) AND THEIR METABOLITES IN BIOLOGICAL SAMPLES | 7 | 7 |
| 512 | 10 | 38 | 1029 1990 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 10(4):281-294 HUANG PHT; MCBRIDE WG THALIDOMIDE INDUCED ALTERATION IN SECONDARY STRUCTURE OF RAT EMBRYONIC DNA INVIVO | 6 | 12 |
| 513 | 10 | 25 | 1146 1994 JOURNAL OF HEPATOLOGY 21(4):496-499 MCCORMICK PA; SCOTT F; EPSTEIN O; BURROUGHS AK; SCHEUER PJ; MCINTYRE N THALIDOMIDE AS THERAPY FOR PRIMARY BILIARY-CIRRHOSIS - A DOUBLE-BLIND PLACEBO-CONTROLLED PILOT-STUDY | 6 | 11 |
| 514 | 10 | 27 | 1152 1994 LIFE SCIENCES 55(2):77-92 NOGUEIRA AC; NEUBERT R; HELGE H; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .3. SIMULTANEOUS UP-REGULATION AND DOWN-REGULATION OF DIFFERENT INTEGRIN RECEPTORS ON HUMAN WHITE BLOOD-CELLS | 56 | 63 |
| 515 | 10 | 14 | 1197 1995 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 233(2):90-93 GUEXCROSIER Y; PITTET N; HERBORT CP THE EFFECT OF THALIDOMIDE AND SUPIDIMIDE ON ENDOTOXIN-INDUCED UVEITIS IN RATS | 5 | 6 |
| 516 | 10 | 25 | 1199 1995 IMMUNOPHARMACOLOGY 31(1):109-116 SHANNON EJ; SANDOVAL F THALIDOMIDE INCREASES THE SYNTHESIS OF IL-2 IN CULTURES OF HUMAN MONONUCLEAR-CELLS STIMULATED WITH CONCANAVALIN-A, STAPHYLOCOCCAL-ENTEROTOXIN-A, AND PURIFIED PROTEIN DERIVATIVE | 34 | 37 |
| 517 | 10 | 14 | 1204 1995 JOURNAL OF LIQUID CHROMATOGRAPHY 18(2):297-309 DELON A; FAVRELIERE S; COUET W; COURTOIS PH; BOUQUET S RAPID AND SENSITIVE DETERMINATION OF THALIDOMIDE IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 5 | 5 |
| 518 | 10 | 18 | 1235 1996 ANTI-CANCER DRUGS 7(3):339-343 Minchinton AI; Fryer KH; Wendt KR; Clow KA; Hayes MMM The effect of thalidomide on experimental tumors and metastases | 29 | 50 |
| 519 | 10 | 22 | 1240 1996 ARCHIVES OF TOXICOLOGY 70(11):749-756 Schmahl HJ; Dencker L; Plum C; Chahoud I; Nau H Stereoselective distribution of the teratogenic thalidomide analogue EM12 in the early embryo of marmoset monkey, Wistar rat and NMRI mouse | 3 | 7 |
| 520 | 10 | 13 | 1249 1996 BONE MARROW TRANSPLANTATION 17(2):291-293 Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GAR Thalidomide responsive chronic pulmonary GVHD | 8 | 14 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 521 | 10 | 36 | 1254 1996 CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 81(3):219-223 Klausner JD; Freedman VH; Kaplan G Thalidomide as an anti-TNF-alpha inhibitor: Implications for clinical use | 39 | 56 |
| 522 | 10 | 20 | 1281 1996 JOURNAL OF SURGICAL RESEARCH 63(1):143-146 Schmidt H; Rush B; Simonian G; Murphy T; Hsieh J; Condon M Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats | 8 | 17 |
| 523 | 10 | 14 | 1292 1996 PEDIATRIC INFECTIOUS DISEASE JOURNAL 15(5):465-467 DeVincenzo JP; Burchet SK Prolonged thalidomide therapy for human immunodeficiency virus-associated recurrent severe esophageal and oral aphthous ulcers | 5 | 7 |
| 524 | 10 | 11 | 1306 1997 AMERICAN JOURNAL OF GASTROENTEROLOGY 92(1):169-170 Ball SC; Sepkowitz KA; Jacobs JL Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: Case report and review | 12 | 13 |
| 525 | 10 | 12 | 1310 1997 ANALYTICA CHIMICA ACTA 339(1-2):91-97 Simmons BR; Lush RM; Figg WD A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum | 8 | 10 |
| 526 | 10 | 16 | 1368 1997 LEPROSY REVIEW 68(1):61-66 Powell RJ; GardnerMedwin JMM Guideline for the clinical use and dispensing of thalidomide (Reprinted from the Postgraduate Medical Journal, vol 70, pg 901-904, 1994) | 1 | 3 |
| 527 | 10 | 55 | 1473 1998 PAIN 74(1):83-91 Sommer C; Marziniak M; Myers RR The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve | 5 | 54 |
| 528 | 10 | 31 | 1526 1999 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 118(2):315-321 Oliver SJ; Freeman SL; Corral LG; Ocampo CJ; Kaplan G Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis | 9 | 13 |
| 529 | 10 | 18 | 1560 1999 JOURNAL OF CHROMATOGRAPHY B 723(1-2):255-264 Meyring M; Strickmann D; Chankvetadze B; Blaschke G; Desiderio C; Fanali S Investigation of the in vitro biotransformation of R-(+)- thalidomide by HPLC, nano-HPLC, CEC and HPLC-APCI-MS | 8 | 20 |
| 530 | 10 | 48 | 1563 1999 JOURNAL OF IMMUNOLOGY 163(1):380-386 Corral LG; Haslett PAJ; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha | 77 | 122 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 531 | 10 | 28 | 1567 1999 JOURNAL OF NEURO-ONCOLOGY 43(2):109-114 Moreira AL; Friedlander DR; Shif B; Kaplan G; Zagzag D Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro | 22 | 36 |
| 532 | 10 | 37 | 1588 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1565-1571 Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeldis J; Barlogie B; Siegel D; Crowley J Antitumor activity of thalidomide in refractory multiple myeloma. | 284 | 548 |
| 533 | 10 | 22 | 1595 1999 PEDIATRICS 103(6):1295-1297 Shek LPC; Lee YS; Lee BW; Lehman TJA Thalidomide responsiveness in an infant with Behcet's syndrome | 10 | 16 |
| 534 | 10 | 20 | 1616 2000 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(2):171-174 Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L Thalidomide and thrombosis. | 25 | 27 |
| 535 | 10 | 31 | 1632 2000 BLOOD 96(9):2943-2950 Hideshima T; Chauhan D; Shima Y; Raje N; Davies FE; Tai YT; Treon SP; Lin B; Schlossman RL; Richardson P; Muller G; Stirling DI; Anderson KC Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy | 89 | 172 |
| 536 | 10 | 34 | 1711 2000 EUROPEAN JOURNAL OF PHARMACOLOGY 391(1-2):97-103 Ribeiro RA; Vale ML; Ferreira SH; Cunha FQ Analgesic effect of thalidomide on inflammatory pain | 3 | 16 |
| 537 | 10 | 28 | 1759 2000 MAYO CLINIC PROCEEDINGS 75(9):897-901 Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed multiple myeloma | 56 | 85 |
| 538 | 10 | 37 | 1791 2000 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(1):35-47 Fort DJ; Stover EL; Bantle JA; Finch RA Evaluation of the developmental toxicity of thalidomide using Frog Embryo Teratogenesis Assay-Xenopus (FETAX): Biotransformation and detoxification | 6 | 8 |
| 539 | 10 | 38 | 1881 2001 BONE MARROW TRANSPLANTATION 28(12):1145-1150 Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation | 3 | 5 |
| 540 | 10 | 51 | 1899 2001 CANCER LETTERS 163(2):191-200 Myoung H; Hong SD; Kim YY; Hong SP; Kim MJ Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma | 4 | 10 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 541 | 10 | 46 | 1922 2001 ELECTROPHORESIS 22(15):3185-3190 Schoetz G; Trapp O; Schurig V Determination of the enantiomerization barrier of thalidomide by dynamic capillary electrokinetic chromatography | 1 | 4 |
| 542 | 10 | 27 | 1957 2001 JOURNAL OF CLINICAL IMMUNOLOGY 21(5):357-364 Prehn JL; Landers C; Muller GW; Man HW; Stirling DI; Targan SR Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues | 3 | 3 |
| 543 | 10 | 15 | 1965 2001 JOURNAL OF INFECTIOUS DISEASES 184(9):1192-1196 Hanekom WA; Hughes J; Haslett PAJ; Apolles P; Ganiso V; Allin R; Goddard E; Hussey GD; Kaplan G The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children | 3 | 3 |
| 544 | 10 | 19 | 1975 2001 LEUKEMIA 15(8):1274-1276 Rajkumar SV; Dispenzieri A; Fonseca R; Lacy MQ; Geyer S; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide for previously untreated indolent or smoldering multiple myeloma | 28 | 43 |
| 545 | 10 | 40 | 2005 2001 SEMINARS IN ONCOLOGY 28(4):62-66 Figg WD; Arlen P; Gulley J; Fernandez P; Noone M; Fedenko K; Hamilton M; Parker C; Kruger EA; Pluda J; Dahut WL A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer | 15 | 37 |
| 546 | 10 | 36 | 2134 2002 BRITISH JOURNAL OF CANCER 87(10):1166-1172 Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects | 9 | 15 |
| 547 | 10 | 15 | 2217 2002 JOURNAL OF CLINICAL GASTROENTEROLOGY 35(2):149-150 Kane S; Stone LJ; Ehrenpreis E Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab - A case series | 3 | 5 |
| 548 | 10 | 22 | 2242 2002 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 29(4):761-766 Liu T; Li MX; Li QY Electrochemical behavior of thalidomide | 0 | 0 |
| 549 | 10 | 33 | 2315 2003 ANNALS OF PHARMACOTHERAPY 37(4):571-576 Thompson JL; Hansen LA Thalidomide dosing in patients with relapsed or refractory multiple myelorna | 0 | 0 |
| 550 | 10 | 16 | 2323 2003 ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX 96(10):1006-1010 Jego C; Barbou F; Laurent P; Gisserot O; Cellarier G; Bonal J; Bouchiat C; Landais C; de Jaureguiberry JP; Dussarat GV Left atrial thrombus in the course of multiple myeloma treated with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 551 | 10 | 16 | 2485 2003 JOURNAL OF INFECTION 47(3):251-255 Roberts MTM; Mendelson M; Meyer P; Carmichael A; Lever AML The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports | 0 | 0 |
| 552 | 10 | 26 | 2492 2003 JOURNAL OF NEURO-ONCOLOGY 64(3):193-201 Gelati M; Corsini E; Frigerio S; Pollo B; Broggi G; Croci D; Silvani A; Boiardi A; Salmaggi A Effects of thalidomide on parameters involved in angiogenesis: an in vitro study | 0 | 0 |
| 553 | 10 | 14 | 2499 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(4):548-552 Hall VC; El-Azhary RA; Bouwhuis S; Rajkumar SV Dermatologic side effects of thalidomide in patients with multiple myeloma | 3 | 4 |
| 554 | 10 | 11 | 2519 2003 LEUKEMIA 17(9):1914-1915 Damaj G; Lefrere F; Delarue R; Varet B; Furman R; Hermine O Thalidomide therapy induces response in relapsed mantle cell lymphoma | 0 | 0 |
| 555 | 10 | 37 | 2549 2003 PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE 19(6):272-280 Lu KQ; Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways | 0 | 0 |
| 556 | 10 | 48 | 2552 2003 RHEUMATIC DISEASE CLINICS OF NORTH AMERICA 29(3):481-+ Davis JC; Huang F; Maksymowych W New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate | 0 | 0 |
| 557 | 10 | 33 | 2557 2003 SEMINARS IN HEMATOLOGY 40(4):17-22 Rajkumar SV Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease | 0 | 0 |
| 558 | 10 | 60 | 2569 2004 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 19(1):79-88 Austin AS; Mahida YR; Clarke D; Ryder SD; Freeman JG A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis | 0 | 0 |
| 559 | 10 | 44 | 2580 2004 ARCHIVES OF DERMATOLOGY 140(3):277-280 Caradona S; Jacobe H Thalidomide as a potential treatment for scleromyxedema | 0 | 0 |
| 560 | 10 | 33 | 2607 2004 CELL BIOLOGY INTERNATIONAL 28(3):237-242 Ergun MA; Konac E; Erbas D; Ekmekci A Apoptosis and nitric oxide release induced by thalidomide, gossypol and dexamethasone in cultured human chronic myelogenous leukemic K-562 cells | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 561 | 10 | 20 | 2611 2004 CLINICAL CANCER RESEARCH 10(12):4192-4197 Ng SSW; Macpherson GR; Gutschow M; Eger K; Figg WD Antitumor effects of thalidomide analogs in human prostate cancer Xenografts implanted in immunodeficient mice | 0 | 0 |
| 562 | 10 | 29 | 2614 2004 CYTOKINE 26(4):145-148 Rosinol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Blade J; Montserrat E Response to thalidomide in multiple myeloma: impact of angiogenic factors | 0 | 0 |
| 563 | 10 | 18 | 2658 2004 LEUKEMIA & LYMPHOMA 45(1):113-116 Anagnostopoulos A; Hamilos G; Zorzou MP; Grigoraki V; Anagnostou D; Dimopoulos MA Discordant response or progression in patients with myeloma treated with thalidomide-based regimens | 0 | 0 |
| 564 | 10 | 32 | 2673 2004 MELANOMA RESEARCH 14(1):57-62 Pawlak WZ; Legha SS Phase II study of thalidomide in patients with metastatic melanoma | 0 | 0 |
| 565 | 9 | 13 | 85 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 86(10):462-& [Anon] THALIDOMIDE AND CONGENITAL MALFORMATIONS | 1 | 0 |
| 566 | 9 | 12 | 264 1964 AMERICAN HEART JOURNAL 67(2):184-& MARTIN JK CONGENITAL MALFORMATIONS ASSOCIATED WITH THALIDOMIDE + THEIR MANAGEMENT | 0 | 0 |
| 567 | 9 | 25 | 375 1966 DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY 8(6):761-& GORDON G MECHANISM OF THALIDOMIDE DEFORMITIES CORRELATED WITH PATHOGENIC EFFECTS OF PROLONGED DOSAGE IN ADULTS | 5 | 5 |
| 568 | 9 | 18 | 408 1966 SCIENCE 153(3733):310-& FOX RR; SAWIN PB; CRARY DD; WUEST HM INTRAVENOUS INJECTION OF THALIDOMIDE IN PREGNANT RABBITS | 6 | 7 |
| 569 | 9 | 66 | 465 1968 JOURNAL OF PHARMACEUTICAL SCIENCES 57(5):757-& SHEALY YF; OPLIGER CE; MONTGOME.JA SYNTHESIS OF D-AND L-THALIDOMIDE AND RELATED STUDIES | 12 | 29 |
| 570 | 9 | 54 | 514 1971 ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE 194(1):39-& LOCKER D; SUPERSTI.E; SULMAN FG MECHANISM OF PUSH AND PULL PRINCIPLE .8. ENDOCRINE EFFECTS OF THALIDOMIDE AND ITS ANALOGUES | 4 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 571 | 9 | 21 | 590 1974 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 24(10):1616-1619 KOHLER F; KOCH H TERATOLOGY STUDY ON THALIDOMIDE-LIKE COMPOUNDS K-2004 AND K-2604 IN MOUSE AND RAT | 9 | 21 |
| 572 | 9 | 24 | 845 1984 BIOCHEMICAL PHARMACOLOGY 33(9):1471-1477 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - ACTIVATION OF THALIDOMIDE AND THALIDOMIDE ANALOGS TO PRODUCTS THAT INHIBIT THE ATTACHMENT OF CELLS TO CONCANAVALIN A COATED PLASTIC SURFACES | 15 | 24 |
| 573 | 9 | 144 | 856 1984 JOURNAL OF THEORETICAL BIOLOGY 110(3):461-486 SHULL GE DIFFERENTIAL INHIBITION OF PROTEIN-SYNTHESIS - A POSSIBLE BIOCHEMICAL-MECHANISM OF THALIDOMIDE TERATOGENESIS | 4 | 6 |
| 574 | 9 | 13 | 880 1985 BRITISH JOURNAL OF DERMATOLOGY 113:141-144 POWELL RJ; ALLEN BR; JENKINS JS; STEELE L; HUNNEYBALL I; MAURICE PDL; LITTLEWOOD SM INVESTIGATION AND TREATMENT OF OROGENITAL ULCERATION - STUDIES ON A POSSIBLE MODE OF ACTION OF THALIDOMIDE | 7 | 9 |
| 575 | 9 | 21 | 1070 1992 NEW ENGLAND JOURNAL OF MEDICINE 326(16):1055-1058 VOGELSANG GB; FARMER ER; HESS AD; ALTAMONTE V; BESCHORNER WE; JABS DA; CORIO RL; LEVIN LS; COLVIN OM; WINGARD JR; SANTOS GW THALIDOMIDE FOR THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE | 166 | 253 |
| 576 | 9 | 13 | 1085 1993 ARCHIVES OF DERMATOLOGY 129(12):1548-1550 HOLM AL; BOWERS KE; MCMEEKIN TO; GASPARI AA CHRONIC CUTANEOUS LUPUS-ERYTHEMATOSUS TREATED WITH THALIDOMIDE | 16 | 19 |
| 577 | 9 | 25 | 1117 1994 ARCHIVES OF DERMATOLOGICAL RESEARCH 286(6):347-349 TSAMBAOS D; BOLSEN K; GEORGIOU S; MONASTIRLI A; GOERZ G EFFECTS OF ORAL THALIDOMIDE ON RAT-LIVER AND SKIN MICROSOMAL P450 ISOZYME ACTIVITIES AND ON URINARY PORPHYRIN EXCRETION - INTERACTION WITH ORAL HEXACHLOROBENZENE | 14 | 15 |
| 578 | 9 | 34 | 1142 1994 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 16(4):717-729 SHANNON EJ; HOWE RC; MCLEAN K; HASTINGS RC THALIDOMIDE DOES NOT PERTURB CD2, CD4, CD5, CD8, HLA-DR, OR HLA-A, HLA-B, HLA-C MOLECULES IN-VITRO ON THE MEMBRANES OF CELLS WITH IMMUNE POTENTIAL | 5 | 5 |
| 579 | 9 | 18 | 1165 1995 ACTA NEUROPATHOLOGICA 89(5):415-419 SCHRODER JM; SELLHAUS B; WOHRMANN T; KOGEL B; ZWINGENBERGER K INHIBITORY EFFECTS OF THALIDOMIDE ON CELLULAR PROLIFERATION, ENDONEURIAL EDEMA AND MYELIN PHAGOCYTOSIS DURING EARLY WALLERIAN DEGENERATION | 6 | 9 |
| 580 | 9 | 19 | 1171 1995 ARCHIVES OF DERMATOLOGY 131(9):1032-1035 GUILLAUME JC; MOULIN G; DIENG MT; POLI F; MOREL P; SOUTEYRAND P; BONNETBLANC JM; CLAUDY A; DANIEL F; VAILLANT L; BERNARD P; BOUILLIE MC; BOURNERIAS I; DENOEUX JP; LAMBERT D; LEONARD F; CHAUMEIL JC; REVUZ J CROSSOVER STUDY OF THALIDOMIDE VS PLACEBO IN JESSNERS LYMPHOCYTIC INFILTRATION OF THE SKIN | 12 | 17 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 581 | 9 | 12 | 1230 1996 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 53(4):368-& Weidle PJ Thalidomide for aphthous ulcers in patients infected with the human immunodeficiency virus | 5 | 5 |
| 582 | 9 | 11 | 1250 1996 BRITISH MEDICAL JOURNAL 313(7054):377-378 Powell RJ New roles for thalidomide | 18 | 24 |
| 583 | 9 | 14 | 1263 1996 GASTROINTESTINAL ENDOSCOPY 44(6):729-731 Bellomo A; SchorrLesnick B Thalidomide treatment for idiopathic esophageal ulcers in patients with HIV | 0 | 1 |
| 584 | 9 | 28 | 1267 1996 IMMUNOPHARMACOLOGY 31(2-3):213-221 Geitz H; Handt S; Zwingenberger K Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade | 70 | 89 |
| 585 | 9 | 51 | 1297 1996 TERATOLOGY 54(3):126-134 Smith DM; Torres RD; Stephens TD Mesonephros has a role in limb development and is related to thalidomide embryopathy | 0 | 5 |
| 586 | 9 | 21 | 1342 1997 INFLAMMATION RESEARCH 46(10):392-397 Schneider J; Bruckmann W; Zwingenberger K Extravasation of leukocytes assessed by intravital microscopy: Effect of thalidomide | 5 | 13 |
| 587 | 9 | 10 | 1426 1998 CLINICAL AND EXPERIMENTAL DERMATOLOGY 23(3):141-141 Georgala S; Katoulis AC; Hasapi V; Koumantaki-Mathioudaki E Thalidomide treatment for hypertrophic lupus erythematosus | 3 | 3 |
| 588 | 9 | 27 | 1429 1998 CLINICAL PHARMACOLOGY & THERAPEUTICS 64(6):597-602 Trapnell CB; Donahue SR; Collins JM; Flockhart DA; Thacker D; Abernethy DR Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone | 13 | 15 |
| 589 | 9 | 10 | 1431 1998 DRUG SAFETY 19(5):339-341 Smithells D Does thalidomide cause second generation birth defects? | 4 | 4 |
| 590 | 9 | 41 | 1446 1998 JOURNAL OF INFECTIOUS DISEASES 177(6):1563-1572 Tsenova L; Sokol K; Freedman VH; Kaplan G Combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death | 14 | 26 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 591 | 9 | 27 | 1530 1999 CLINICAL PHARMACOLOGY & THERAPEUTICS 65(5):483-490 Scheffler MR; Colburn W; Kook KA; Thomas SD Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics | 12 | 12 |
| 592 | 9 | 33 | 1546 1999 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 237(12):952-961 Joussen AM; Germann T; Kirchhof B Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency | 4 | 8 |
| 593 | 9 | 9 | 1561 1999 JOURNAL OF CHROMATOGRAPHY B 734(2):203-210 Torano JS; Verbon A; Guchelaar HJ Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection | 8 | 8 |
| 594 | 9 | 24 | 1615 2000 AMERICAN JOURNAL OF PATHOLOGY 156(1):151-158 Sauer H; Gunther J; Hescheler J; Wartenberg M Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals | 16 | 33 |
| 595 | 9 | 19 | 1680 2000 BONE MARROW TRANSPLANTATION 26(8):865-869 Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Wagner J; Enright H Response to thalidomide therapy in refractory chronic graft-versus-host disease | 11 | 17 |
| 596 | 9 | 15 | 1745 2000 JOURNAL OF INFECTIOUS DISEASES 181(5):1813-1816 Juffermans NP; Verbon A; Olszyna DP; van Deventer SJH; Speelman P; van der Poll T Thalidomide suppresses up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4(+) T cells in humans | 3 | 5 |
| 597 | 9 | 16 | 1756 2000 LIFE SCIENCES 66(2):133-141 Thiel R; Kastner U; Neubert R Expression of adhesion receptors on rat limb bud cells and results of treatment with a thalidomide derivative | 3 | 4 |
| 598 | 9 | 27 | 1784 2000 SEMINARS IN HEMATOLOGY 37(1):1-4 Anderson KC Thalidomide: Therapeutic potential in hematologic malignancies | 6 | 8 |
| 599 | 9 | 18 | 1829 2001 BLOOD 98(1):210-216 Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin B; Podar K; Gupta D; Chauhan D; Treon SP; Richardson PG; Schlossman RL; Morgan GJ; Muller GW; Stirling DI; Anderson KC Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | 48 | 91 |
| 600 | 9 | 21 | 1830 2001 BLOOD 98(2):492-494 Barlogie B; Desikan R; Eddlemon P; Spencer T; Zeldis J; Munshi N; Badros A; Zangari M; Anaissie E; Epstein J; Shaughnessy J; Ayers D; Spoon D; Tricot G Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients | 66 | 111 |
Page 2: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22